Comparison of the 2017 ACC/AHA Hypertension Guideline with Earlier Guidelines on Estimated Reductions in Cardiovascular Disease
- 137 Downloads
Purpose of Review
To review the recommendations of the 2017 American College of Cardiology/American Heart Association hypertension guideline and to compare it with previous guidelines on potential cardiovascular disease (CVD) and mortality risk reductions.
Compared with previous guidelines, the 2017 hypertension guideline increased the prevalence of hypertension and the number of adults recommended for antihypertensive therapy in the US population. Based on data from recent analyses, the new guideline effectively directs antihypertensive therapy toward individuals at higher CVD risk. Two recent analyses using US national data estimated that implementation of the 2017 hypertension guideline could further reduce hundreds of thousands of CVD events and deaths compared with previous guidelines. However, the new guideline might increase the number of adverse events. The new guideline also improves the number of individuals needed to treat to prevent CVD events and deaths, suggesting implementation is cost-effective.
Implementation of the 2017 hypertension guideline is projected to substantially reduce CVD events and deaths in the USA but might increase the number of adverse events. Future research is needed to implement and scale up effective, equitable, and sustainable strategies for applying the new guideline in daily clinical practice.
KeywordsCardiovascular disease Mortality Population Epidemiology Hypertension guidelines
This work was supported by the National Institute of General Medical Sciences (P20GM109036) and the National Heart, Lung, and Blood Institute (R01HL133790) of the National Institutes of Health, Bethesda, MD.
Compliance with Ethical Standards
Conflict of Interest
The authors declare no conflicts of interest relevant to this manuscript.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 3.Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mmHg, 1990-2015. JAMA. 2017;317:165–82.Google Scholar
- 14.•• Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018;71:e127–248 This is the most recent 2017 hypertension guideline and contains detailed recommendations regarding the prevention, detection, evaluation, and management of hypertension and cites substantial evidence supporting the recommendations.CrossRefGoogle Scholar
- 15.•• Bundy JD, Mills KT, Chen J, Li C, Greenland P, He J. Estimating the association of the 2017 and 2014 hypertension guidelines with cardiovascular events and deaths in US adults. JAMA Cardiol. 2018;3:572–81 This is one of two separate, but complementary, modeling analyses that estimates the potential risk reductions of cardiovascular disease and all-cause deaths in the US population. Additionally, this paper provides the most updated nationally representative data on the prevalence of hypertension under the 2014 and 2017 hypertension guidelines. CrossRefGoogle Scholar
- 16.•• Bress AP, Colantonio LD, Cooper RS, Kramer H, Booth JN, Odden MC, et al. Potential Cardiovascular Disease Events Prevented with Adoption of the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline. Circulation. 2019;139:24–36 This is one of two separate, but complementary, modeling analyses that estimates the potential risk reductions of cardiovascular disease and all-cause deaths in the US population..CrossRefGoogle Scholar
- 17.• Muntner P, Shimbo D, Carey RM, Charleston JB, Gaillard T, Misra S, et al. Measurement of blood pressure in humans: a scientific statement from the american heart association. Hypertension. 2019. This scientific statement describes, in detail, appropriate measurement of blood pressure and represents an important reference for a crucial aspect of hypertension control. Google Scholar
- 20.Qaseem A, Wilt TJ, Rich R, Humphrey LL, Frost J, Forciea MA. Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2017;166:430–7.CrossRefGoogle Scholar
- 22.• Muntner P, Carey RM, Gidding S, Jones DW, Taler SJ, Wright JT, et al. Potential U.S. population impact of the 2017 ACC/AHA high blood pressure guideline. Circulation. 2018;137:109–18 This paper provides nationally representative data on the prevalence of hypertension under the JNC7 and 2017 hypertension guidelines.CrossRefGoogle Scholar
- 29.Chang TI, Sarnak MJ. Intensive blood pressure targets and kidney disease. Clin J Am Soc Nephrol. 2018;CJN.02010218.Google Scholar
- 36.Peters R, Beckett N, Falaschetti E, Thijs L, Bulpitt C, Rockwood K, et al. No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Med. 2015;13:1–8.CrossRefGoogle Scholar
- 38.Reboussin DM, Allen NB, Griswold ME, Guallar E, Hong Y, Lackland DT, et al. Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/ APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018;71:2176–98.Google Scholar
- 39.Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation. 2013;00:000–000.Google Scholar
- 41.The Atherosclerosis Risk in Communities (ARIC) study, design and objectives: the ARIC investigators. Am J Epidemiol. 1989;129:687–702.Google Scholar
- 42.Fried LP, Borhani N, Enright P, Furberg CD, Gardin JM, Kronmal RA, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991;Google Scholar
- 50.•• Colantonio LD, Booth JN, Bress AP, Whelton PK, Shimbo D, Levitan EB, et al. 2017 ACC/AHA blood pressure treatment guideline recommendations and cardiovascular risk. J Am Coll Cardiol. 2018;72:1187–97 This paper provides observational data supporting the recommendations of the 2017 hypertension guideline, including for the baseline risk–targeted approach in those with stage 1 hypertension.CrossRefGoogle Scholar
- 53.Fryar C, Ostchega Y, Hales C, Zhang G, Kruszon-Moran D. Hypertension prevalence and control among adults: United States, 2015–2016. NCHS Data Brief, No. 289. Hyattsville, MD: National Center for Health Statistics; 2017.Google Scholar
- 55.• Mills KT, Obst KM, Shen W, Molina S, Zhang H-J, He H, et al. Comparative effectiveness of implementation strategies for blood pressure control in hypertensive patients: a systematic review and meta-analysis of implementation strategies for blood pressure control. Ann Intern Med. 2018;168:110–20 This paper provides a comparison of several strategies for implementation of blood pressure control using a meta-analytic framework.CrossRefGoogle Scholar